In the enlarged image inside the magnifying glass, a drug-entrapping coating attached to the inner surface of the graft can be observed. (From: ITMO University/Yulia Chapurina
Scientists from the International Laboratory of Solution Chemistry of Advanced Materials and Technologies at ITMO University have developed artificial blood vessels resistant to thrombosis. A matrix that coats the vessel inner surface can retain a clot-dissolving enzyme. The finding was published in the Journal of Medicinal Chemistry.
Cardiovascular diseases sometimes derive in the implantation of vascular grafts, artificial blood vessels that restore blood circulation. The problem with vascular grafts is their propensity to form clots. Patients usually need to take anticoagulants for life or undergo surgery.
To avoid this kind of problems, the researchers from ITMO University designed a vascular graft lined with a film of aluminum oxide nanorods blended with molecules of a thrombolytic enzyme (urokinase-type plasminogen activator). The film is a porous matrix that lets in only certain molecules. One of them is plasminogen, a natural proenzyme found in blood. When plasminogen interacts with the plasminogen activator, plasmin -a molecule that dissolves clots- forms. In this way the film, adhered to the inner part of the blood vessel, keeps a constant concentration of plasmin, avoiding clot formation.
Vladimir Vinogradov and his team tested the vascular grafts efficiency by forming artificial clots with blood plasma and thrombin. The clots where dissolved even at the stage of formation.
Recently designed vascular grafts already use drug-eluting technology, but they release drugs to the bloodstream and thus have a limited lifetime. Vinogradov’s team, on the other hand, has designed an encapsulating shell that keeps the enzymes in place for a virtually unlimited amount of time.
In the future, the same technology could be applied to other organs, keeping a given drug in the porous matrix to dissolve crystal formation or defective molecular accumulations.
Celestina is a science and medical writer specializing in creating clear, accurate, and engaging content across a range of deliverables, including manuscripts, newsletters, advisory board materials, infographics and promotional materials, tailored to healthcare professionals and scientific audiences.
Her work spans diverse therapeutic areas such as oncology, ophthalmology, infectious diseases, cardiovascular health, rare diseases and more. With a Master’s in Infectious Diseases and a postgraduate diploma in Scientific Writing and Medical Journalism, I bring both scientific rigor and editorial precision to every project. Fluent in Mandarin, I also support the development and review of Traditional Chinese medical content to ensure scientific accuracy.
We use cookies to provide you with the best possible experience. They also allow us to analyze user behavior in order to constantly improve the website for you. Privacy Policy
Privacy Preference
Strictly NecessaryAlways on
Performance
Functionality
Targeting or Advertising
Strictly Necessary
These cookies are necessary for the site to work and cannot be switched off. They are set in response to things you do — signing in, submitting a form, or recording the privacy choices on this panel. They also cover the spam protection on our forms. You can block them in your browser, but parts of the site will stop working.
Performance
Analytics that tell us which pages are read and how people arrive, so we know what to write more of. We use Google Analytics for this. Decline and it still counts the visit, but without cookies and without anything that could identify you.
Functionality
Remembers preferences so the site behaves consistently between visits — things like dismissed notices and choices you have already made. Declining loses those conveniences; nothing else breaks.
Targeting or Advertising
Used to measure sponsorships and show relevant promotions. Labcritics does not sell your data, and sponsors never receive it. Declining means promotions are untargeted — you will see the same number of them.
